Repligen (RGEN) Misses Q1 EPS by 2c ; Offers Guidance
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $169.04 +1.32%
Financial Fact:
Cost of product revenue: 11.24M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Cost of product revenue: 11.24M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q1 EPS of $0.28, $0.02 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $151.3 million versus the consensus estimate of $150.06 million.
GUIDANCE:
Repligen sees FY2024 EPS of $1.42-$1.49, versus the consensus of $1.46. Repligen sees FY2024 revenue of $620-650 million, versus the consensus of $637.8 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
- INVO Fertility (IVF) Tops Q2 EPS by 105c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
